This document discusses STEM education programs supported by PhRMA member companies. It finds that over 30 PhRMA member programs focus on increasing diversity in STEM fields. These programs have impacted over 1.6 million students and 17,500 teachers over the last 5 years. However, U.S. students lag behind globally in science and math test scores, and the U.S. now ranks 20th in STEM degrees awarded. To maintain its position of innovation leadership, the U.S. needs to produce 1 million more STEM graduates over the next decade. PhRMA members support over 90 STEM programs through funding, scholarships, and hands-on learning to help address this need.
STEM: Building a 21st Century Workforce to Develop Tomorrow's New MedicinesPhRMA
Â
Continued scientific and technological innovations are critical to fostering sustained economic growth, global competitiveness, and most importantly, helping patients live longer, healthier, and more productive lives. The U.S. innovative biopharmaceutical industry is committed to building on new scientific discoveries and technological advances, relying on a workforce with education and skills in science, technology, engineering, and math (STEM).
2014 Report: Medicines in Development for HIV/AIDSPhRMA
Â
Biopharmaceutical Company Researchers Are Developing More Than 40 Medicines and Vaccines For HIV Infection Treatment and Prevention
Globally, approximately 35 million people are infected with human immunodeficiency virus (HIV), the virus that causes
acquired immune deficiency syndrome (AIDS). However, new infections have dropped by 38 percent since 2001, according to UNAIDS, the Joint United Nations Programme on HIV/AIDS.
2015 Report: Medicines in Development for Heart Disease & StrokePhRMA
Â
According to the American Heart Association, someone in the United States dies from cardiovascular disease every 40 seconds, and more than 85 million Americans have at least one form of the disease. Heart disease has been the leading cause of death in the United States since 1921, but these numbers are declining. Read this report by PhRMA - in partnership with the Association of Black Cardiologists - on the nearly 200 medicines in development for heart disease & stroke.
STEM: Building a 21st Century Workforce to Develop Tomorrow's New MedicinesPhRMA
Â
Continued scientific and technological innovations are critical to fostering sustained economic growth, global competitiveness, and most importantly, helping patients live longer, healthier, and more productive lives. The U.S. innovative biopharmaceutical industry is committed to building on new scientific discoveries and technological advances, relying on a workforce with education and skills in science, technology, engineering, and math (STEM).
2014 Report: Medicines in Development for HIV/AIDSPhRMA
Â
Biopharmaceutical Company Researchers Are Developing More Than 40 Medicines and Vaccines For HIV Infection Treatment and Prevention
Globally, approximately 35 million people are infected with human immunodeficiency virus (HIV), the virus that causes
acquired immune deficiency syndrome (AIDS). However, new infections have dropped by 38 percent since 2001, according to UNAIDS, the Joint United Nations Programme on HIV/AIDS.
2015 Report: Medicines in Development for Heart Disease & StrokePhRMA
Â
According to the American Heart Association, someone in the United States dies from cardiovascular disease every 40 seconds, and more than 85 million Americans have at least one form of the disease. Heart disease has been the leading cause of death in the United States since 1921, but these numbers are declining. Read this report by PhRMA - in partnership with the Association of Black Cardiologists - on the nearly 200 medicines in development for heart disease & stroke.
2016 Report: Medicines in Development for Alzheimer's DiseasePhRMA
Â
Today, more than 5 million Americans have Alzheimerâs disease. The disease devastates the minds of patients, creates substantial burdens for families and caregivers, and currently costs the health care system more than $200 billion a year. These sobering statistics are projected to get much worse as the 76 million American baby boomers age.
This report shows that America's Biopharmaceutical Research Companies Are Developing More Than 70 Medicines for Alzheimerâs Disease
2014 Report: Medicines in Development for ArthritisPhRMA
Â
Arthritis is part of a group of related musculoskeletal diseases consisting of more than 100 different conditions that affect more than 52 million people in the United States, according to the U.S. Centers for Disease Control and Prevention (CDC).
2014 Report: Medicines in Development for Older AmericansPhRMA
Â
As life expectancy continues to climbâup to more than 81 years for women and 76 years for menâthe growing number of Americans age 65 and older will face new challenges from chronic conditions such as arthritis, Alzheimerâs disease, cardiovascular disease and diabetes, which impact their health, productivity and independence. Those diseases not only impact the individuals living with them, but burden their families and cost the health care system billions of dollars.
Biopharmaceutical research companies are developing 435 medicines targeting 15 leading chronic conditions affecting seniorsâAlzheimerâs and dementia, anemia, arthritis, benign prostatic hyperplasia, cataracts and glaucoma, chronic
kidney disease, chronic obstructive pulmonary disease (COPD), depression, diabetes, heart failure, hyperlipidemia,
hypertension, hypothyroidism and ischemic heart disease.
Social Media Report - Household Cleaning Products October-November 2016Unmetric
Â
Explore the social media efforts of household cleaning products on facebook, twitter and instagram in this cross-channel report.
Find out audience growth, top posts and see how the brands engaged best with their audience.
2014 Profile: Biopharmaceutical Research IndustryPhRMA
Â
Biopharmaceutical science is a complex, collaborative, resource-intensive enterprise. It requires a highly skilled workforce, sustained investment, and long-term vision. Critical to its success are policies and regulations that foster innovation and broad access to new medicines. By working togetherâon the science, the research and the policiesâwe
can help ensure that medicines live up to patientsâ hope for new solutions to our greatest health care challenges.
On June 21st, PwCâs Health Research Institute (HRI) released its annual Medical Cost Trend: Behind the Numbers 2017 report. PwCâs HRI anticipates a 6.5% growth rate for 2017âthe same as was projected for 2016. The report identifies the key inflators and deflators as well as historical context to better understand the medical cost trend for 2017. Increases in the trend due to utilization of convenient care access points and an uptick in behavioral healthcare benefits for employees are being offset by more aggressive strategies by pharmacy benefit
Findings on health information technology and electronic health recordsDeloitte United States
Â
The Deloitte Center for Health Solutions 2016 Survey of US Physicians set out to understand physician adoption and perception of key market trends around health information technology and electronic health record data. Explore key survey findings to discover where physicians find the most value, barriers to adoption, and what they want next. http://deloi.tt/2d3b4w6
Social media report - Automobile Brands January 1st - December 31st 2016Unmetric
Â
Explore the social media performance of automobile brands on Facebook, Twitter and Instagram. Access key takeaways and top line metrics on engagement, campaigns and top posts.
TMT Outlook 2017: A new wave of advances offer opportunities and challengesDeloitte United States
Â
Important trends continue to shape the technology, media, and telecommunications (TMT) industry. What developments should you anticipate in 2017? https://subscriptions.deloitte.com/default.aspx?eventid=1323075
2016 Report: Medicines in Development for Alzheimer's DiseasePhRMA
Â
Today, more than 5 million Americans have Alzheimerâs disease. The disease devastates the minds of patients, creates substantial burdens for families and caregivers, and currently costs the health care system more than $200 billion a year. These sobering statistics are projected to get much worse as the 76 million American baby boomers age.
This report shows that America's Biopharmaceutical Research Companies Are Developing More Than 70 Medicines for Alzheimerâs Disease
2014 Report: Medicines in Development for ArthritisPhRMA
Â
Arthritis is part of a group of related musculoskeletal diseases consisting of more than 100 different conditions that affect more than 52 million people in the United States, according to the U.S. Centers for Disease Control and Prevention (CDC).
2014 Report: Medicines in Development for Older AmericansPhRMA
Â
As life expectancy continues to climbâup to more than 81 years for women and 76 years for menâthe growing number of Americans age 65 and older will face new challenges from chronic conditions such as arthritis, Alzheimerâs disease, cardiovascular disease and diabetes, which impact their health, productivity and independence. Those diseases not only impact the individuals living with them, but burden their families and cost the health care system billions of dollars.
Biopharmaceutical research companies are developing 435 medicines targeting 15 leading chronic conditions affecting seniorsâAlzheimerâs and dementia, anemia, arthritis, benign prostatic hyperplasia, cataracts and glaucoma, chronic
kidney disease, chronic obstructive pulmonary disease (COPD), depression, diabetes, heart failure, hyperlipidemia,
hypertension, hypothyroidism and ischemic heart disease.
Social Media Report - Household Cleaning Products October-November 2016Unmetric
Â
Explore the social media efforts of household cleaning products on facebook, twitter and instagram in this cross-channel report.
Find out audience growth, top posts and see how the brands engaged best with their audience.
2014 Profile: Biopharmaceutical Research IndustryPhRMA
Â
Biopharmaceutical science is a complex, collaborative, resource-intensive enterprise. It requires a highly skilled workforce, sustained investment, and long-term vision. Critical to its success are policies and regulations that foster innovation and broad access to new medicines. By working togetherâon the science, the research and the policiesâwe
can help ensure that medicines live up to patientsâ hope for new solutions to our greatest health care challenges.
On June 21st, PwCâs Health Research Institute (HRI) released its annual Medical Cost Trend: Behind the Numbers 2017 report. PwCâs HRI anticipates a 6.5% growth rate for 2017âthe same as was projected for 2016. The report identifies the key inflators and deflators as well as historical context to better understand the medical cost trend for 2017. Increases in the trend due to utilization of convenient care access points and an uptick in behavioral healthcare benefits for employees are being offset by more aggressive strategies by pharmacy benefit
Findings on health information technology and electronic health recordsDeloitte United States
Â
The Deloitte Center for Health Solutions 2016 Survey of US Physicians set out to understand physician adoption and perception of key market trends around health information technology and electronic health record data. Explore key survey findings to discover where physicians find the most value, barriers to adoption, and what they want next. http://deloi.tt/2d3b4w6
Social media report - Automobile Brands January 1st - December 31st 2016Unmetric
Â
Explore the social media performance of automobile brands on Facebook, Twitter and Instagram. Access key takeaways and top line metrics on engagement, campaigns and top posts.
TMT Outlook 2017: A new wave of advances offer opportunities and challengesDeloitte United States
Â
Important trends continue to shape the technology, media, and telecommunications (TMT) industry. What developments should you anticipate in 2017? https://subscriptions.deloitte.com/default.aspx?eventid=1323075
Our future depends on a STEM educated workforce. STEM (Science, Technology, Engineering and Math) education and activities, early in a student's life, makes a significant difference in careers and college education. Please take 30 seconds and urge Congress to focus on STEM in the update and reauthorization of the ESEA (No Child Left Behind) Education Act, by clicking here: http://www.congressweb.com/stemedcoalition/24
Today NewSchools Ignite is releasing âPromising Developments in Science Edtech,â a summary report of our findings and the lessons learned from the Science Learning Challenge market research and cohort experience. The report compiles the key insights weâve gleaned, and presents them in three sections: why science education matters, challenges facing K-12 science learning, and opportunities for edtech to support science learning.
Promising Developments in Edtech for ScienceJohn Terada
Â
We are releasing âPromising Developments in Edtech for Scienceâ, a summary report of our findings and the lessons learned from the Science Learning Challenge market research and cohort experience. The report compiles the key insights weâve gleaned, and presents them in three sections: why science education matters, challenges facing K-12 science learning, and opportunities for edtech to support science learning.
Dr. Freeman A. Hrabowski, III, president of the University of Maryland, Baltimore County (UMBC), offers practical and scalable solutions to that problem in a new policy paper released by The McGraw-Hill Research Foundation. In the paper, Institutional Change in Higher Education: Innovation and Collaboration, Hrabowski discusses how his institution has addressed the shortage of STEM graduates, particularly among groups that have been underrepresented in these fields, including minorities, women, and students from low-income backgrounds. UMBC has been recognized widely as a leader in higher education innovation. For three years in a row, the U.S. News and World Report Americaâs Best Colleges Guide has ranked the university number one among âUp-and-Comingâ national universities.
Memo to Massachusetts is the cover story in our latest Vision Project Report, "Degrees of Urgency: Why Massachusetts Needs More College Graduates Now." It describes the current climate of Massachusetts public higher education, and the perfect storm of factors facing the state-- our economy's need for more college graduates, projected declines in the number of high school graduates, and the cumulative impact of historic underfunding of public higher education.
Learn more at www.mass.edu/visionproject
An Overview of Computer Science Master Degree Programs in the State of Califo...IJITE
Â
A sound education in information technology fuels the success of individuals as well as corporations in the
modern life. Information technology offers numerous opportunities but faces unique challenges in the
United States. In a populous state like California, where Computer Science (CS) has been taught at the
college level since the 1950s, these problems are even acute. This article provides an overview of the
current state of affairs in CS in California. We include wisdom from lessons learned from efforts to offer
quality education in both public and private universities in California. In particular, we focus on the
differential school system and the educational landscape of CS education in this state.
AN OVERVIEW OF COMPUTER SCIENCE MASTER DEGREE PROGRAMS IN THE STATE OF CALIFO...IJITE
Â
A sound education in information technology fuels the success of individuals as well as corporations in the modern life. Information technology offers numerous opportunities but faces unique challenges in the United States. In a populous state like California, where Computer Science (CS) has been taught at the college level since the 1950s, these problems are even acute. This article provides an overview of the current state of affairs in CS in California. We include wisdom from lessons learned from efforts to offer quality education in both public and private universities in California. In particular, we focus on the
differential school system and the educational landscape of CS education in this state.
Landscape of the MSCS Programs in Californiabaidya
Â
A sound education in information technology fuels the success of individuals as well as corporations in modern life. Information technology offers numerous opportunities but faces unique challenges in the United States. In a populous state like California, where Computer Science (CS) has been taught at the
college level since the 1950s, these problems are even acute. This article provides an overview of the
current state of affairs in CS in California. We include wisdom from lessons learned from efforts to offer
quality education in both public and private universities in California. In particular, we focus on the
differential school system and the educational landscape of CS education in this state.
High school graduates have trouble finding good jobs. Thereâs a mismatch in our economy, and it is about to get dramatically worse. Business Forward is joined by Carmel Martin, Managing Director of XQ Institute, for a discussion on how to redesign our schools for the 21st century.
Prescription Medicines Costs in Context - June 2019PhRMA
Â
We are in a new era of medicine where breakthrough science is transforming care with innovative treatment approaches and enabling us to more effectively treat chronic disease, the biggest cost driver.
Prescription Medicines - Insulin Costs in ContextPhRMA
Â
A century ago, patients were treated with animal insulins. Today, biopharmaceutical companies produce insulins that operate at the molecular level, more closely resembling insulin released naturally in the body and more effectively managing the disease. The options available today also help meet a wide range of unmet needs, providing patients with the tools necessary to stay adherent and healthy â saving costs throughout the health care system. However, this innovation isnât enough if patients canât afford their insulin and other medicines at the pharmacy.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
Â
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Acute scrotum is a general term referring to an emergency condition affecting the contents or the wall of the scrotum.
There are a number of conditions that present acutely, predominantly with pain and/or swelling
A careful and detailed history and examination, and in some cases, investigations allow differentiation between these diagnoses. A prompt diagnosis is essential as the patient may require urgent surgical intervention
Testicular torsion refers to twisting of the spermatic cord, causing ischaemia of the testicle.
Testicular torsion results from inadequate fixation of the testis to the tunica vaginalis producing ischemia from reduced arterial inflow and venous outflow obstruction.
The prevalence of testicular torsion in adult patients hospitalized with acute scrotal pain is approximately 25 to 50 percent
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Â
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? â The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
Â
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganongâs Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Prix Galien International 2024 Forum ProgramLevi Shapiro
Â
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMENâS HEALTH: FERTILITY PRESERVATION
- WHATâS NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
Â
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years â 64.8%, 20 years â 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP â more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0âN12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0âN12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
1. To Develop Tomorrowâs New Medicines
Building a 21st
Century Workforce
1+2
PhRMA Member Companies Support
STEM Programs Across the U.S.
Impact & Reach
OVER 30 PHRMA MEMBER PROGRAMS
ARE FOCUSING ON INCREASING
DIVERSITY IN STEM FIELDS.
Key Report Findings: Biopharmaceutical Industry Advancing STEM5
ï”ï STEM workforce is vital to the future of U.S. economy and global
competitiveness â STEM workers account for over 50% of the nationâs
sustained economic growth.1
ï”ï STEM workforce is particularly important to biopharmaceutical
manufacturing, which has 5X greater concentration of STEM jobs
compared to rest of economy.2
ï”ï U.S. high school students rank 28th
in science and 36th
in math among
65 countries. Shanghai currently ranks 1st
for both subjects.3
ï”ï Once a leader in STEM education, the U.S. now ranks 20th
among all
nations in proportion of degrees awarded in science and engineering
fieldsâJapan and China award twice the U.S. share.4
ï”ï As other countries continue to make substantial investments in growing
their STEM talent, U.S. investments in STEM education continue to
decline, risking our position as the global innovation leader.
State of STEM Education in U.S.
Total number of
STEM programs
supported
Number of
employee
volunteers
Number of
employee hours
volunteered
Percentage of
Industry-sponsored
STEM programs
focused on K-12
Number of
individual
STEM-related
grants awarded
Total STEM
education program
funding provided
$100M4,500 27,000 85% 60090
ï”ï PhRMA member companies and their foundations support over 90 STEM programs
focused on both students and teachers.
ï”ï Support ranges from funding third-party STEM education initiatives, to supporting STEM
scholarships, and providing hands-on learning opportunities in company laboratories.
ï”ï Member companies sponsor 14 national-level programs, with additional local-level
programs being supported in 26 states, Washington D.C. and Puerto Rico, with a larger
concentration of activity in states with deeper industry presence.
Over the last five years, PhRMA member
company STEM programs have impacted over
1.6 million students and 17,500 teachers.
85% of programs are focused on the way K-12
STEM education is taught in the U.S. by engaging
younger students and early education teachers.
U.S. needs to produce 1 million
additional STEM graduates over
the next decade to maintain its
position as the worldâs leader
in science and technology
innovation.
--PCAST
Source: Presidentâs Council of Advisors on Science and
Technology, âEngage to Excel: Producing One Million
Additional College Graduates with Degrees in Science,
Technology, Engineering, and Mathematics,â February 2012.
1
U.S. Department of Labor, âThe STEM Workforce Challenge: The Role of the Public Workforce System in a
National Solution for a Competitive Science, Technology, Engineering, and Mathematics (STEM) Workforce,â April 2007.
2
Battelle Analysis of Bureau of Labor Statistics, Occupational Employment Statistics data, 2012.
3
Organization for Economic Co-operation and Development (OECD), Programme for International Student Assessment
(PISA), 2013.
4
National Science Board, âScience and Engineering Indicators 2012.â
5
Battelle Technology Partnership Practice, "STEM: Building a 21st Century Workforce to Develop Tomorrow's New
Medicines," January 2014. Data includes activities supported by PhRMA member companies or their foundations.